Posted by Michael Wonder on 27 Feb 2020
Zogenix announces FDA extension of review period for Fintepla in Dravet syndrome
27 February 2020 - Zogenix today announced that the U.S. FDA has extended the review period for the new drug application for Fintepla for the treatment of seizures associated with Dravet syndrome.
The new Prescription Drug User Fee Act target action date has been extended by three months to 25 June 2020.
